(NASDAQ: INSM) Insmed's forecast annual revenue growth rate of 52.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.21%.
Insmed's revenue in 2026 is $1,137,635,000.On average, 25 Wall Street analysts forecast INSM's revenue for 2026 to be $401,603,584,017, with the lowest INSM revenue forecast at $355,525,086,884, and the highest INSM revenue forecast at $432,613,757,443. On average, 25 Wall Street analysts forecast INSM's revenue for 2027 to be $645,535,722,868, with the lowest INSM revenue forecast at $554,252,254,614, and the highest INSM revenue forecast at $756,910,289,398.
In 2028, INSM is forecast to generate $876,146,590,036 in revenue, with the lowest revenue forecast at $701,004,624,630 and the highest revenue forecast at $1,169,214,567,062.